Is CNTA or CNTX more undervalued in 2026?

CirclFi compares Centessa Pharmaceuticals plc (CNTA) and Context Therapeutics Inc. (CNTX) using 13 institutional-grade valuation models. CNTA has a Quality of Company score of 5.9/10 while CNTX scores 4.5/10.

Which is a better buy — CNTA or CNTX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CNTA and CNTX valuations compare?

CNTA at $39.81 and CNTX at $2.83 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CNTA vs CNTX Valuation Comparison 2026 — Intrinsic Value Analysis

CNTA

Biotechnology

Centessa Pharmaceuticals plc

Quality

5.9

out of 10

Value Trap

SAFE

Price

$39.81

Last close

Models

10/13

Active

CNTX

Biotechnology

Context Therapeutics Inc.

Quality

4.5

out of 10

Value Trap

SAFE

Price

$2.83

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	CNTA Fair Value	CNTA Upside	CNTX Fair Value	CNTX Upside
Bayesian DCF	Intrinsic	$11.91	-70.1%	$1.08	-61.7%
Earnings Power Value	Intrinsic	$16.41	-58.4%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.49	-98.8%	$0.10	-95.5%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CNTA vs CNTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CNTA vs CNTX — Which Stock Is More Undervalued?

CNTA scores higher with a 5.9/10 quality rating vs CNTX's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Centessa Pharmaceuticals plc (CNTA) and Context Therapeutics Inc. (CNTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CNTA currently trades at $39.81 with a QOC of 5.9/10, while CNTX trades at $2.83 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).